SB

Sagimet Biosciences Inc.

SGMT·NASDAQ

$6.86

+1.3%
HealthcareBiotechnology

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

At a Glance

Live Snapshot
Market Cap$223.51M
EPS-1.5800
P/E Ratio-4.34
Earnings Date08/12/2026

sgmt

Other Non-Current Assets

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

SB

Sagimet Biosciences Inc. Competitors Analysis of Other Non-Current Assets

SGMT · NASDAQ
CompanyOther Non-Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
7.98M
71.1%35.0%18.0%
3.14M
31.0%59.4%N/A
312.00K
0.0%-28.8%2.0%
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
672.00K
-7.2%N/AN/A
2.15M
10.7%17.2%N/A
92.00K
-51.4%0.0%-17.2%
257.00K
-2.2%-15.4%10.3%
0.00
N/AN/AN/A
2.00M
-10.8%-13.5%N/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
1.51M
N/AN/AN/A
SB

Sagimet Biosciences Inc. Fair Value Envelope

SGMT · NASDAQ

Our analysis suggests that SGMT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.86, this represents a potential HIDDEN relative to our calculated worth for Sagimet Biosciences Inc..

Intrinsic Value
Current Price: $6.86